Perspectives of Rheumatologists on the Type 1 and 2 Systemic Lupus Erythematosus Model.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
29 Sep 2024
29 Sep 2024
Historique:
revised:
30
08
2024
received:
07
06
2024
accepted:
10
09
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
The Type 1 and 2 systemic lupus erythematosus (SLE) Model was developed to encapsulate all signs and symptoms that patients with SLE experience. Our previous qualitative work demonstrated the model accurately reflects the lived experience of people living with SLE. The objective of this study was to present the Type 1 and 2 SLE Model to rheumatologists to understand how the model fits with their experiences treating patients with SLE. We conducted a qualitative descriptive study using semistructured interviews with rheumatologists. Rheumatologists were asked about their general impression of the Type 1 and 2 SLE Model, how the model does or does not fit within their approach to treating patients with SLE, the utility of the model in clinical practice, and any suggested changes. Applied thematic analysis identified salient themes. We interviewed 13 rheumatologists. The majority of rheumatologists approved of the model and found it useful to guide therapy and clinical decision-making. Several rheumatologists thought the model was helpful for patient education to manage expectations about differences between Type 1 and Type 2 symptoms and treatments. A few rheumatologists expressed concern that the model could lead to an overdiagnosis of SLE. The Type 1 and 2 SLE Model was accepted by most rheumatologists interviewed and welcomed as a useful approach to identifying and treating symptoms in patients with SLE. Future studies will determine how implementing the Type 1 and 2 SLE Model affects patient understanding, the physician-patient relationship, and clinical outcomes.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pfizer
Organisme : NIH HHS
ID : 1KL2TR002554
Pays : United States
Organisme : NIH HHS
ID : R01MD018977
Pays : United States
Informations de copyright
© 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Boomsma MM, Bijl M, Stegeman CA, et al. Patients’ perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2002;47(2):196–201.
Jump RL, Robinson ME, Armstrong AE, et al. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005;32(9):1699–1705.
Moses N, Wiggers J, Nicholas C, et al. Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus. Patient Educ Couns 2005;57(1):30–38.
Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006;55(4):628–635.
Kiani AN, Petri M. Quality‐of‐life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep 2010;12(4):250–258.
Kiani AN, Strand V, Fang H, et al. Predictors of self‐reported health‐related quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2013;52(9):1651–1657.
Torrente‐Segarra V, Carbonell‐Abelló J, Castro‐Oreiro S, et al. Association between fibromyalgia and psychiatric disorders in systemic lupus erythematosus. Clin Exp Rheumatol 2010;28(6 suppl 63):S22–S26.
Pettersson S, Lövgren M, Eriksson LE, et al. An exploration of patient‐reported symptoms in systemic lupus erythematosus and the relationship to health‐related quality of life. Scand J Rheumatol 2012;41(5):383–390.
Karol DE, Criscione‐Schreiber LG, Lin M, et al. Depressive symptoms and associated factors in systemic lupus erythematosus. Psychosomatics 2013;54(5):443–450.
Nelson W, Katz P, Daly RP, et al. Lupus flare activity from the patient perspective [abstract]. Arthritis Rheumatol 2018;70(suppl 9). https://acrabstracts.org/abstract/lupus‐flare‐activity‐from‐the‐patient‐perspective/.
Rogers JL, Eudy AM, Pisetsky D, et al. Using clinical characteristics and patient‐reported outcome measures to categorize systemic lupus erythematosus subtypes. Arthritis Care Res (Hoboken) 2021;73(3):386–393.
Ward MM, Sundaramurthy S, Lotstein D, et al. Participatory patient‐physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;49(6):810–818.
Bennett JK, Fuertes JN, Keitel M, et al. The role of patient attachment and working alliance on patient adherence, satisfaction, and health‐related quality of life in lupus treatment. Patient Educ Couns 2011;85(1):53–59.
Beusterien K, Bell JA, Grinspan J, et al. Physician‐patient interactions and outcomes in systemic lupus erythematosus (SLE): a conceptual model. Lupus 2013;22(10):1038–1045.
Drenkard C, Bao G, Lewis TT, et al. Physician‐patient interactions in African American patients with systemic lupus erythematosus: demographic characteristics and relationship with disease activity and depression. Semin Arthritis Rheum 2019;48(4):669–677.
Neville C, Clarke AE, Joseph L, et al. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol 2000;27(3):675–679.
Alarcón GS, McGwin Jr G, Brooks K, et al; LUMINA Study Group. Lupus in Minority populations: Nature versus nurture. Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores. Arthritis Rheum 2002;47(4):408–413.
Yen JC, Abrahamowicz M, Dobkin PL, et al. Determinants of discordance between patients and physicians in their assessment of lupus disease activity. J Rheumatol 2003;30(9):1967–1976.
Leong KP, Chong EY, Kong KO, et al; Tan Tock Seng Hospital (TTSH) Lupus Study Group. Discordant assessment of lupus activity between patients and their physicians: the Singapore experience. Lupus 2010;19(1):100–106.
Pettersson S, Svenungsson E, Gustafsson J, et al. A comparison of patients’ and physicians’ assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire. Scand J Rheumatol 2017;46(6):474–483.
Elera‐Fitzcarrald C, Vega K, Gamboa‐Cárdenas RV, et al. Discrepant perception of lupus disease activity: a comparison between patients’ and physicians’ disease activity scores. J Clin Rheumatol 2020;26(7S suppl 2):S165–S169.
Rogers JL, Clowse MEB, McKenna K, et al. Patient and physician perspectives of systemic lupus erythematosus flare: a qualitative study. J Rheumatol 2024;51(5):488–494.
Hale ED, Treharne GJ, Lyons AC, et al. “Joining the dots” for patients with systemic lupus erythematosus: personal perspectives of health care from a qualitative study. Ann Rheum Dis 2006;65(5):585–589.
Pisetsky DS, Clowse MEB, Criscione‐Schreiber LG, et al. A novel system to categorize the symptoms of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2019;71(6):735–741.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 evisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46(3):319–329.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011;38(6):1113–1122.
Wolfe F, Walitt BT, Rasker JJ, et al. The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. J Rheumatol 2015;42(8):1494–1501.
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29(2):288–291.
Eudy AM, Clowse ME, Corneli A, et al. The Type 1 & 2 systemic lupus erythematosus model: perspectives of people living with systemic lupus erythematosus. Lupus 2024;33(3):266–272.
Rogers JL, Clowse MEB, Pisetsky DS, et al. Evaluation of Type 2 SLE symptoms in patients with a range of lupus nephritis activity. Clin Rheumatol 2024;43(4):1319–1326.
Eudy AM, Reeve BB, Coles T, et al. The use of patient‐reported outcome measures to classify type 1 and 2 systemic lupus erythematosus activity. Lupus 2022;31(6):697–705.
Sun K, Eudy AM, Harris N, et al. Using PROMIS‐29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study. J Patient Rep Outcomes 2023;7(1):136.
Eudy AM, Rogers JL, Corneli A, et al. Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms. Lupus Sci Med 2022;9(1): e000705.
Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006;18(1):59–82.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64(8):2677–2686.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71(9):1400–1412.
Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41(5):778–799.
Vincent A, Lahr BD, Wolfe F, et al. Prevalence of fibromyalgia: a population‐based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) 2013;65(5):786–792.
Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38(1):19–28.
Buskila D, Press J, Abu‐Shakra M. Fibromyalgia in systemic lupus erythematosus: prevalence and clinical implications. Clin Rev Allergy Immunol 2003;25(1):25–28.
Friedman AW, Tewi MB, Ahn C, et al; LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups: XV. Prevalence and correlates of fibromyalgia. Lupus 2003;12(4):274–279.
Huang FF, Fang R, Nguyen MH, et al. Identifying co‐morbid fibromyalgia in patients with systemic lupus erythematosus using the Multi‐Dimensional Health Assessment Questionnaire. Lupus 2020;29(11):1404–1411.
Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994;37(8):1181–1188.
Leuchten N, Milke B, Winkler‐Rohlfing B, et al; on behalf of the SLE Classification Criteria Steering Committee. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus 2018;27(9):1431–1436.
Goebel A, Andersson D, Helyes Z, et al. The autoimmune aetiology of unexplained chronic pain. Autoimmun Rev 2022;21(3):103015.
Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest 2021;131(13):e144201.